Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329279 | 0.84 | RNPEP (0.31) | RNPEP | |
| SCHEMBL5330977 | 0.83 | TSHR (0.34) | TSHRMETAP2METAP1 | |
| SCHEMBL28637319 | 0.82 | RNPEP (0.46) | RNPEPFOLH1LMNAMAPK1METAP2 | |
| SCHEMBL5329985 | 0.82 | BHMT (0.32) | — | |
| SCHEMBL23079505 | 0.81 | RNPEP (0.44) | RNPEPFOLH1LMNAMAPK1METAP2 | |
| SCHEMBL4953075 | 0.81 | RNPEP (0.44) | RNPEPFOLH1CYP2C9LMNATSHR | |
| SCHEMBL4949335 | 0.81 | RNPEP (0.44) | RNPEPFOLH1CYP2C9LMNAMAPK1 | |
| SCHEMBL5325063 | 0.80 | MAPT (0.33) | CYP2C9MAPK1 | |
| SCHEMBL4954245 | 0.79 | RNPEP (0.46) | RNPEPFOLH1CYP2C9LMNAMAPK1 | |
| SCHEMBL9332345 | 0.78 | RNPEP (0.48) | RNPEPFOLH1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007147155-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | PNLIP, ELOVL1, ELOVL5 | RNPEP 3086/4885FOLH1 1682/4885CYP2C9 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.